Early proof of principle work has been conducted in collaboration with the Elizabeth Macarthur Institute, New South Wales, Australia.

ImmBio has entered into a research, development and end-product licensing arrangement with The Aeras Global TB Foundation.  It has extensive resources in Rockville, US and is supported by The Bill & Melinda Gates Foundation. Aeras facilities includes cGMP fermentation capacity. ImmBio has worked with the National Institute for Biological Standards and Control and also supports a TB programme at the University of Surrey.

The leading influenza programme involves a number of collaborations and technical advisors, including the Department of Pathology, University of Cambridge and the School of Biological Sciences at the University of Reading. Process development work is managed by Eden BioDesign at the National Biomanufacturing Centre, Speke.

The Meningitis programme is undertaken with the Meningitis Research Group, School of Medical Sciences, University of Bristol.

The Hepatitis work is conducted in association with the Institute of Cell & Molecular Science, Queen Mary's School of Medicine and Dentistry, The Royal London Hospital.